{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T17:25:20Z","timestamp":1788715520073,"version":"build-2803163510"},"reference-count":77,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T00:00:00Z","timestamp":1695427200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.autrev.2023.103451","type":"journal-article","created":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T11:24:16Z","timestamp":1695468256000},"page":"103451","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Low-dose intravenous immunoglobulin (IVIg) in different immune-mediated conditions"],"prefix":"10.1016","volume":"22","author":[{"given":"Maria Giovanna","family":"Danieli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Antonelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Auria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Buti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehuda","family":"Shoenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.autrev.2023.103451_bb0005","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s281-001-8170-y","article-title":"Immunomodulation of autoimmune diseases by high-dose intravenous immunoglobulins","volume":"23","author":"Rauova","year":"2001","journal-title":"Springer Semin Immunopathol"},{"key":"10.1016\/j.autrev.2023.103451_bb0010","series-title":"Old Herborn University Seminar Monograph","first-page":"85","article-title":"Intravenous immunoglobulin (IVIg) in autoimmune diseases - expanding indications and increasing specificity","author":"Sherer","year":"2001"},{"issue":"12","key":"10.1016\/j.autrev.2023.103451_bb0015","first-page":"754","article-title":"The efficacy of intravenous immunoglobulin in Guillain-Barr\u00e9 syndrome: the experience of a Tertiary Medical Center","volume":"20","author":"Shalem","year":"2018","journal-title":"Isr Med Assoc J"},{"issue":"10","key":"10.1016\/j.autrev.2023.103451_bb0020","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1177\/0961203317696589","article-title":"Intravenous immunoglobulin: a biological corticosteroid-sparing agent in some autoimmune conditions","volume":"26","author":"Watad","year":"2017","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2023.103451_bb0025","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1007\/s13311-021-01108-4","article-title":"Update on intravenous immunoglobulin in neurology: modulating neuro-autoimmunity, evolving factors on efficacy and dosing and challenges on stopping chronic IVIg therapy","volume":"18","author":"Dalakas","year":"2021","journal-title":"Neurotherapeutics"},{"issue":"10","key":"10.1016\/j.autrev.2023.103451_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102366","article-title":"Next-generation Fc receptor-targeting biologics for autoimmune diseases","volume":"18","author":"Zuercher","year":"2019","journal-title":"Autoimmun Rev"},{"issue":"3","key":"10.1016\/j.autrev.2023.103451_bb0035","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S1246-7820(03)00035-1","article-title":"Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases","volume":"10","author":"Bayry","year":"2003","journal-title":"Transfus Clin Biol"},{"issue":"11","key":"10.1016\/j.autrev.2023.103451_bb0040","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/intimm\/dxx039","article-title":"IVIG-mediated effector functions in autoimmune and inflammatory diseases","volume":"29","author":"Galeotti","year":"2017","journal-title":"Int Immunol"},{"key":"10.1016\/j.autrev.2023.103451_bb0045","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1093\/ajhp\/zxz233","article-title":"Optimization of intravenous immune globulin use at a comprehensive cancer center","volume":"76","author":"Figgins","year":"2019","journal-title":"Am J Health-Syst Pharm"},{"issue":"6","key":"10.1016\/j.autrev.2023.103451_bb0050","first-page":"293","article-title":"Chronic inflammatory demyelinating polyradiculoneuropathy: revisiting the role of intravenous immmunoglobulins","volume":"15","author":"Chapman","year":"2013","journal-title":"Isr Med Assoc J"},{"issue":"2","key":"10.1016\/j.autrev.2023.103451_bb0055","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1080\/08916930500059633","article-title":"IVIg therapy in autoimmunity and related disorders: our experience with a large cohort of patients","volume":"38","author":"Shoenfeld","year":"2005","journal-title":"Autoimmunity"},{"key":"10.1016\/j.autrev.2023.103451_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2019.116497","article-title":"Immunoglobulin administration for the treatment of CIDP: IVIG or SCIG?","volume":"408","author":"Allen","year":"2020","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.autrev.2023.103451_bb0065","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1196\/annals.1361.121","article-title":"Response of vasculitic peripheral neuropathy to intravenous immunoglobulin","volume":"1051","author":"Levy","year":"2005","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.autrev.2023.103451_bb0070","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/978-1-62703-586-6_18","article-title":"Idiotype-specific intravenous immunoglobulin (IVIG) for therapy of autoimmune diseases","volume":"1060","author":"Blank","year":"2014","journal-title":"Methods Mol Biol"},{"issue":"21","key":"10.1016\/j.autrev.2023.103451_bb0075","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1056\/NEJMra1009433","article-title":"Intravenous immune globulin in autoimmune and inflammatory diseases","volume":"367","author":"Gelfand","year":"2012","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.autrev.2023.103451_bb0080","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1385\/CRIAI:29:3:185","article-title":"Facing the enigma of immunomodulatory effects of intravenous immunoglobulin","volume":"29","author":"Sapir","year":"2005","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.autrev.2023.103451_bb0085","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1385\/CRIAI:29:3:165","article-title":"Intravenous immunoglobulin","volume":"29","author":"Shoenfeld","year":"2005","journal-title":"Clinic Rev Allerg Immunol"},{"key":"10.1016\/j.autrev.2023.103451_bb0090","series-title":"Autoimmunity: From Bench to Bedside","article-title":"Intravenous immunoglobulin-customized therapy","author":"Zandman-Goddard","year":"2013"},{"key":"10.1016\/j.autrev.2023.103451_bb0095","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.autrev.2011.08.004","article-title":"B cells are resistant to immunomodulation by \u2018IVIg-educated\u2019 dendritic cells","volume":"11","author":"Maddur","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2023.103451_bb0100","doi-asserted-by":"crossref","DOI":"10.1177\/1756286421997381","article-title":"The importance of FcRn in neuro-immunotherapies: From IgG catabolism, FCGRT gene polymorphisms, IVIg dosing and efficiency to specific FcRn inhibitors","volume":"14","author":"Dalakas","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.autrev.2023.103451_bb0105","author":"Italian Medicines Agency (AIFA)"},{"issue":"2","key":"10.1016\/j.autrev.2023.103451_bb0110","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s12016-011-8278-7","article-title":"Long-term therapy with intravenous immunoglobulin is beneficial in patients with autoimmune diseases","volume":"42","author":"Zandman-Goddard","year":"2012","journal-title":"Clin Rev Allergy Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2023.103451_bb0115","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1177\/1060028019880300","article-title":"Outcomes associated with standardized ideal body weight dosing of intravenous immune globulin in hospitalized patients: a multicenter study","volume":"54","author":"Grindeland","year":"2020","journal-title":"Ann Pharmacother"},{"issue":"6","key":"10.1016\/j.autrev.2023.103451_bb0120","first-page":"365","article-title":"Diagnosis and management of Kawasaki disease","volume":"91","author":"Saguil","year":"2015","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.autrev.2023.103451_bb0125","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2147\/VHRM.S291762","article-title":"Kawasaki disease: pathology, risks, and management","volume":"18","author":"Seki","year":"2022","journal-title":"Vasc Health Risk Manag"},{"issue":"7","key":"10.1016\/j.autrev.2023.103451_bb0130","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/ped.14656","article-title":"Randomized trial of different initial intravenous immunoglobulin regimens in Kawasaki disease","volume":"63","author":"He","year":"2021","journal-title":"Pediatr Int"},{"issue":"6","key":"10.1016\/j.autrev.2023.103451_bb0135","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s00431-006-0280-3","article-title":"A randomized prospective study on the use of 2 g-IVIG or 1 g-IVIG as therapy for Kawasaki disease","volume":"166","author":"Sakata","year":"2007","journal-title":"Eur J Pediatr"},{"issue":"2","key":"10.1016\/j.autrev.2023.103451_bb0140","doi-asserted-by":"crossref","first-page":"81","DOI":"10.4070\/kcj.2010.40.2.81","article-title":"Effectiveness of medium-dose intravenous immunoglobulin (1 g\/kg) in the treatment of Kawasaki disease","volume":"40","author":"Yeo","year":"2010","journal-title":"Korean Circ J"},{"issue":"3","key":"10.1016\/j.autrev.2023.103451_bb0145","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1017\/S1047951121002237","article-title":"Stratified therapy for Kawasaki disease using a new scoring system to predict the response to a lower dose of intravenous immunoglobulin therapy","volume":"32","author":"Matsuura","year":"2022","journal-title":"Cardiol Young"},{"issue":"12","key":"10.1016\/j.autrev.2023.103451_bb0150","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1007\/s00431-020-03794-2","article-title":"High-dose versus low-dose intravenous immunoglobulin for treatment of children with Kawasaki disease weighing 25 kg or more","volume":"179","author":"Suzuki","year":"2020","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.autrev.2023.103451_bb0155","doi-asserted-by":"crossref","DOI":"10.4414\/smw.2012.13593","article-title":"Treatment of immune thrombocytopenia with intravenous immunoglobulin and insights for other diseases. A historical review","volume":"142","author":"Imbach","year":"2012","journal-title":"Swiss Med Wkly"},{"issue":"3","key":"10.1016\/j.autrev.2023.103451_bb0160","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.hoc.2013.03.001","article-title":"Immune thrombocytopenia","volume":"27","author":"Kistangari","year":"2013","journal-title":"Hematol Oncol Clin North Am"},{"issue":"6","key":"10.1016\/j.autrev.2023.103451_bb0165","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-071644","article-title":"Low-dose intravenous immunoglobulin for children with newly diagnosed immune thrombocytopenia: protocol of a systematic review and meta-analysis","volume":"13","author":"Ren","year":"2023","journal-title":"BMJ Open"},{"issue":"23","key":"10.1016\/j.autrev.2023.103451_bb0170","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"Neunert","year":"2019","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.autrev.2023.103451_bb0175","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/00043426-199705000-00004","article-title":"Safety and efficacy of low-dose intravenous immune globulin (IVIG) treatment for infants and children with immune thrombocytopenic purpura. Low-Dose IVIG Study Group","volume":"19","author":"Warrier","year":"1997","journal-title":"J Pediatr Hematol Oncol"},{"issue":"10","key":"10.1016\/j.autrev.2023.103451_bb0180","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1097\/00043426-200310000-00011","article-title":"Low-dose versus high-dose immunoglobulin for primary treatment of acute immune thrombocytopenic purpura in children: results of a prospective, randomized single-center trial","volume":"25","author":"Benesch","year":"2003","journal-title":"J Pediatr Hematol Oncol"},{"issue":"1","key":"10.1016\/j.autrev.2023.103451_bb0185","first-page":"11","article-title":"Low dose intravenous immunoglobulin for acute immune thrombocytopenic purpura in children","volume":"19","author":"Nuchprayoon","year":"2001","journal-title":"Asian Pac J Allergy Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2023.103451_bb0190","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1046\/j.1365-2141.1999.01766.x","article-title":"Intravenous immunoglobulin for adults with autoimmune thrombocytopenic purpura: results of a randomized trial comparing 0.5 and 1 g\/kg b.w","volume":"107","author":"Godeau","year":"1999","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.autrev.2023.103451_bb0195","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/MBC.0b013e3283401490","article-title":"The efficacy of different dose intravenous immunoglobulin in treating acute idiopathic thrombocytopenic purpura: a meta-analysis of 13 randomized controlled trials","volume":"21","author":"Qin","year":"2010","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"1","key":"10.1016\/j.autrev.2023.103451_bb0200","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3109\/08916934.2015.1104671","article-title":"Different dosages of intravenous immunoglobulin (IVIg) in treating immune thrombocytopenia with long-term follow-up of three years: Results of a prospective study including 167 cases","volume":"49","author":"Zhou","year":"2016","journal-title":"Autoimmunity"},{"issue":"2","key":"10.1016\/j.autrev.2023.103451_bb0205","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/bjh.17692","article-title":"A single 1 g\/kg dose of intravenous immunoglobulin is a safe and effective treatment for immune thrombocytopenia; results of the first HaemSTAR 'Flash-Mob' retrospective study incorporating 961 patients","volume":"196","year":"2022","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.autrev.2023.103451_bb0210","doi-asserted-by":"crossref","first-page":"506.e1","DOI":"10.1016\/j.ajog.2022.04.044","article-title":"Antenatal intravenous immunoglobulins in pregnancies at risk of fetal and neonatal alloimmune thrombocytopenia: comparison of neonatal outcome in treated and nontreated pregnancies","volume":"227","author":"Ernstsen","year":"2022","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.autrev.2023.103451_bb0215","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1159\/000380907","article-title":"Low-dose versus standard-dose intravenous immunoglobulin to prevent fetal intracranial hemorrhage in fetal and neonatal alloimmune thrombocytopenia: a randomized trial","volume":"38","author":"Paridaans","year":"2015","journal-title":"Fetal Diagn Ther"},{"issue":"9","key":"10.1016\/j.autrev.2023.103451_bb0220","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1111\/trf.13712","article-title":"Lower-dose intravenous immunoglobulins for the treatment of fetal and neonatal alloimmune thrombocytopenia: a cohort study","volume":"56","author":"Kamphuis","year":"2016","journal-title":"Transfusion"},{"issue":"2","key":"10.1016\/j.autrev.2023.103451_bb0225","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.autrev.2005.09.002","article-title":"Intravenous immunoglobulin for immunomodulation of systemic lupus erythematosus","volume":"5","author":"Sherer","year":"2006","journal-title":"Autoimmun Rev"},{"issue":"4","key":"10.1016\/j.autrev.2023.103451_bb0230","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.humimm.2005.01.022","article-title":"High-dose intravenous immunoglobulins: an option in the treatment of systemic lupus erythematosus","volume":"66","author":"Toubi","year":"2005","journal-title":"Hum Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2023.103451_bb0235","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1385\/CRIAI:29:3:219","article-title":"Intravenous immunoglobulin therapy and systemic lupus erythematosus","volume":"29","author":"Zandman-Goddard","year":"2005","journal-title":"Clin Rev Allergy Immunol"},{"issue":"13","key":"10.1016\/j.autrev.2023.103451_bb0240","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1177\/0961203319883680","article-title":"Treatment with intravenous immunoglobulins in systemic lupus erythematosus: a single-center experience with 63 patients","volume":"28","author":"Nieto-Aristiz\u00e1bal","year":"2019","journal-title":"Lupus"},{"issue":"11","key":"10.1016\/j.autrev.2023.103451_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103182","article-title":"Efficacy and safety of intravenous immunoglobulin in patients with lupus nephritis: A systematic review of the literature","volume":"21","author":"Cajamarca-Bar\u00f3n","year":"2022","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.autrev.2023.103451_bb0250","first-page":"55","article-title":"Low dose intravenous immunoglobulin in systemic lupus erythematosus: analysis of 62 cases","volume":"10","author":"Sherer","year":"2008","journal-title":"Isr Med Assoc J"},{"issue":"9","key":"10.1016\/j.autrev.2023.103451_bb0255","article-title":"Use of intravenous immunoglobulin therapy at unconventional doses in refractory fulminant systemic lupus erythematosus","volume":"5","author":"Binello","year":"2018","journal-title":"Eur J Case Rep Intern Med"},{"key":"10.1016\/j.autrev.2023.103451_bb0260","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.3389\/fimmu.2019.01090","article-title":"High-dose intravenous immunoglobulin in skin autoimmune disease","volume":"10","author":"Hoffmann","year":"2019","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2023.103451_bb0265","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.jid.2017.01.003","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: associations, outcomes, and pathobiology-thirty years of progress but still much to be done","volume":"137","author":"Stern","year":"2017","journal-title":"J Invest Dermatol"},{"issue":"6","key":"10.1016\/j.autrev.2023.103451_bb0270","doi-asserted-by":"crossref","first-page":"398","DOI":"10.4103\/0378-6323.18943","article-title":"Efficacy of low dose intravenous immunoglobulins in children with toxic epidermal necrolysis: an open uncontrolled study","volume":"71","author":"Mangla","year":"2005","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"4","key":"10.1016\/j.autrev.2023.103451_bb0275","doi-asserted-by":"crossref","first-page":"506","DOI":"10.4103\/0378-6323.113080","article-title":"Low dose intravenous immunoglobulins and steroids in toxic epidermal necrolysis: a prospective comparative open-labelled study of 36 cases","volume":"79","author":"Jagadeesan","year":"2013","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"1","key":"10.1016\/j.autrev.2023.103451_bb0280","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13023-018-0793-7","article-title":"Epidermal necrolysis French national diagnosis and care protocol (PNDS; protocole national de diagnostic et de soins)","volume":"13","author":"Ingen-Housz-Oro","year":"2018","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"10.1016\/j.autrev.2023.103451_bb0285","doi-asserted-by":"crossref","first-page":"895","DOI":"10.3390\/medicina57090895","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of diagnosis and management","volume":"57","author":"Frantz","year":"2021","journal-title":"Medicina (Kaunas)"},{"issue":"12","key":"10.1016\/j.autrev.2023.103451_bb0290","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/nm.1884","article-title":"Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"14","author":"Chung","year":"2008","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.autrev.2023.103451_bb0295","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1067\/mjd.2002.127249","article-title":"Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children","volume":"47","author":"Tristani-Firouzi","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2023.103451_bb0300","series-title":"Annales de dermatologie et de syphilographie. Paris","first-page":"597","article-title":"De la psorospermose folliculaire v\u00e9g\u00e9tante. \u00c9tude anatomo-pathologique d\u2019une affection cutan\u00e9e non d\u00e9crite ou comprise dans le groupe des acn\u00e9s sebac\u00e9es, corn\u00e9es, hypertrophiantes, des k\u00e9ratoses (ichtyoses) folliculaires, etc","volume":"10","author":"Darier","year":"1889"},{"issue":"3","key":"10.1016\/j.autrev.2023.103451_bb0305","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jdcr.2020.01.007","article-title":"Response to low-dose intravenous immunoglobulin in a case of recalcitrant Darier disease","volume":"6","author":"Legrand","year":"2020","journal-title":"JAAD Case Rep"},{"issue":"3","key":"10.1016\/j.autrev.2023.103451_bb0310","doi-asserted-by":"crossref","first-page":"e222","DOI":"10.1111\/pde.12856","article-title":"Netherton syndrome mimicking pustular psoriasis: clinical implications and response to intravenous immunoglobulin","volume":"33","author":"Small","year":"2016","journal-title":"Pediatr Dermatol"},{"issue":"3","key":"10.1016\/j.autrev.2023.103451_bb0315","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jaci.2009.06.009","article-title":"Com\u00e8l-Netherton syndrome defined as primary immunodeficiency","volume":"124","author":"Renner","year":"2009","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2023.103451_bb0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102997","article-title":"Efficacy and safety of intravenous and subcutaneous immunoglobulin therapy in idiopathic inflammatory myopathy: A systematic review and meta-analysis","volume":"21","author":"Goswami","year":"2022","journal-title":"Autoimmun Rev"},{"issue":"Suppl. 4","key":"10.1016\/j.autrev.2023.103451_bb0325","doi-asserted-by":"crossref","first-page":"S256","DOI":"10.1007\/s10072-003-0090-6","article-title":"High-dose intravenous immunoglobulin in inflammatory myopathies: experience based on controlled clinical trials","volume":"24","author":"Dalakas","year":"2003","journal-title":"Neurol Sci"},{"issue":"8","key":"10.1016\/j.autrev.2023.103451_bb0330","doi-asserted-by":"crossref","first-page":"5571","DOI":"10.4049\/jimmunol.179.8.5571","article-title":"Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function","volume":"179","author":"Kessel","year":"2007","journal-title":"J Immunol"},{"issue":"12","key":"10.1016\/j.autrev.2023.103451_bb0335","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.autrev.2014.08.018","article-title":"Subcutaneous IgG in immune-mediate diseases: proposed mechanisms of action and literature review","volume":"13","author":"Danieli","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"14","key":"10.1016\/j.autrev.2023.103451_bb0340","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa2117912","article-title":"Trial of intravenous immune globulin in dermatomyositis","volume":"387","author":"Aggarwal","year":"2022","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.autrev.2023.103451_bb0345","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1346-8138.1999.tb02026.x","article-title":"Low-dose intravenous immunoglobulin therapy for intractable dermatomyositis skin lesions","volume":"26","author":"Sadayama","year":"1999","journal-title":"J Dermatol"},{"key":"10.1016\/j.autrev.2023.103451_bb0350","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.3389\/fimmu.2019.01090","article-title":"High-dose intravenous immunoglobulin in skin autoimmune disease","volume":"10","author":"Hoffmann","year":"2019","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2023.103451_bb0355","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.jaci.2020.02.013","article-title":"Autoimmune bullous skin diseases, pemphigus and pemphigoid","volume":"145","author":"Egami","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.autrev.2023.103451_bb0360","article-title":"Low-dose subcutaneous immunoglobulin is an effective treatment for autoimmune bullous skin disorders: A case report","volume":"8","author":"Streu","year":"2020","journal-title":"SAGE Open Med Case Rep"},{"key":"10.1016\/j.autrev.2023.103451_bb0365","article-title":"Intravenous immunoglobulin treatment in chronic neurological diseases: do we have maintenance dose right?","volume":"2014","author":"Dolezal","year":"2014","journal-title":"Autoimmune Dis"},{"issue":"1","key":"10.1016\/j.autrev.2023.103451_bb0370","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1177\/1756285614563056","article-title":"Switch from intravenous to subcutaneous immunoglobulin in CIDP and MMN: improved tolerability and patient satisfaction","volume":"8","author":"Hadden","year":"2015","journal-title":"Ther Adv Neurol Disord"},{"issue":"2","key":"10.1016\/j.autrev.2023.103451_bb0375","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/ene.14547","article-title":"Chronic immunoglobulin maintenance therapy in myasthenia gravis","volume":"28","author":"Alcantara","year":"2021","journal-title":"Eur J Neurol"},{"issue":"1\u20132","key":"10.1016\/j.autrev.2023.103451_bb0380","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jns.2013.10.043","article-title":"Maintenance IVIg therapy in myasthenia gravis does not affect disease activity","volume":"338","author":"Hellmann","year":"2014","journal-title":"J Neurol Sci"},{"issue":"10","key":"10.1016\/j.autrev.2023.103451_bb0385","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1007\/s00415-021-10544-3","article-title":"Chronic low-dose intravenous immunoglobulins as steroid-sparing therapy in myasthenia gravis","volume":"268","author":"Wilf-Yarkoni","year":"2021","journal-title":"J Neurol"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997223001854?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997223001854?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:28:53Z","timestamp":1761600533000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997223001854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":77,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S1568997223001854"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2023.103451","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low-dose intravenous immunoglobulin (IVIg) in different immune-mediated conditions","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2023.103451","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103451"}}